

May 2026

MEDPACE
Clinical Pharmacology

SRK-439-001 MAD Cohort 8

Study Inpatient dates:

Jun 02-05, 2026
Jul 28-31, 2026

Study Outpatient dates:

Jun 07, 10, 17, 24, 2026
Jul 08, 2026
Aug 02, 05, 12, 26, 2026
Sep 09, 23, 2026
Oct 21, Nov 18, Dec 16, 2026
Jan 13, 2027

Sun	Mon	Tue	Wed	Thu	Fri	Sat
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18 Screening MRI/DEXA Window Opens*	19 Begin medication restrictions	20	21	22	23
24	25 Memorial Day	26	27	28	29 Screening MRI/DEXA Window Closes*	30 Begin exercise, sauna, and steam bath restrictions
31 Begin alcohol restrictions						

Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 57).**
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening.**
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening .**
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study.**
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study.**
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening.**
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**), and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to first Admission (Day -1).**
- Avoid medications that impede coagulation or platelet aggregation **throughout the study.**
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening.**
- Avoid strenuous exercise for **72 hours prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Avoid alcohol **within 48 hours prior to first Admission (Day -1) and throughout the study.**
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to first Admission (Day -1) and throughout the study.**
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to first Admission (Day -1) and throughout the study.**
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study.**
- Avoid the use of saunas or steam baths **within 72 hours prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**

Reminder: COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

***payment to occur within 48 hours after payment visit day**
***MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

June 2026

MEDPACE

Clinical Pharmacology

SRK-439-001 MAD Cohort 8

Study Inpatient dates:

Jun 02-05, 2026
Jul 28-31, 2026

Study Outpatient dates:

Jun 07, 10, 17, 24, 2026
Jul 08, 2026
Aug 02, 05, 12, 26, 2026
Sep 09, 23, 2026
Oct 21, Nov 18, Dec 16, 2026
Jan 13, 2027

Sun	Mon	Tue	Wed	Thu	Fri	Sat
	1 Begin overnight fast	2 Day -1 Admission	3 Day 1 Dose	4 Day 2 Inpatient Begin exercise, sauna, and steam bath restrictions	5 Day 3 Discharge Payment 1*	6 Begin overnight fast
7 Day 5 OPV Begin exercise, sauna, and steam bath restrictions	8	9 Begin overnight fast	10 Day 8 OPV	11	12	13
14 Begin exercise, sauna, and steam bath restrictions	15	16 Begin overnight fast	17 Day 15 OPV Payment 2*	18	19	20
21 Begin exercise, sauna, and steam bath restrictions	22	23 Begin overnight fast	24 Day 22 OPV	25	26	27
28	29	30				

Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 57).**
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening.**
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening .**
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study.**
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study.**
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening.**
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**), and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to first Admission (Day -1).**
- Avoid medications that impede coagulation or platelet aggregation **throughout the study.**
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening.**
- Avoid strenuous exercise for **72 hours prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Avoid alcohol **within 48 hours prior to first Admission (Day -1) and throughout the study.**
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to first Admission (Day -1) and throughout the study.**
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to first Admission (Day -1) and throughout the study.**
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study.**
- Avoid the use of saunas or steam baths **within 72 hours prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**

Reminder: COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

***payment to occur within 48 hours after payment visit day**
***MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

July 2026

MEDPACE
Clinical Pharmacology

SRK-439-001 MAD Cohort 8

Study Inpatient dates:

Jun 02-05, 2026
Jul 28-31, 2026

Study Outpatient dates:

Jun 07, 10, 17, 24, 2026
Jul 08, 2026
Aug 02, 05, 12, 26, 2026
Sep 09, 23, 2026
Oct 21, Nov 18, Dec 16, 2026
Jan 13, 2027

Sun	Mon	Tue	Wed	Thu	Fri	Sat
			1	2	3	4 Independence Day
5 Begin exercise, sauna, and steam bath restrictions	6	7 Begin overnight fast	8 Day 36 OPV Payment 3*	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25 Begin exercise, sauna, and steam bath restrictions
26	27 Day 57 MRI Window Opens* Begin overnight fast	28 Day 57 MRI Window Closes* Day 56 Admission	29 Day 57 Dose	30 Day 58 Inpatient Begin exercise, sauna, and steam bath restrictions	31 Day 59 Discharge Payment 4*	

Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 57).**
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening.**
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening .**
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study.**
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study.**
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening.**
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**), and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to first Admission (Day -1).**
- Avoid medications that impede coagulation or platelet aggregation **throughout the study.**
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening.**
- Avoid strenuous exercise for **72 hours prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Avoid alcohol **within 48 hours prior to first Admission (Day -1) and throughout the study.**
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to first Admission (Day -1) and throughout the study.**
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to first Admission (Day -1) and throughout the study.**
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study.**
- Avoid the use of saunas or steam baths **within 72 hours prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**

Reminder: COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

***payment to occur within 48 hours after payment visit day**
***MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

August 2026

MEDPACE

Clinical Pharmacology

SRK-439-001 MAD Cohort 8

Study Inpatient dates:

Jun 02-05, 2026
Jul 28-31, 2026

Study Outpatient dates:

Jun 07, 10, 17, 24, 2026
Jul 08, 2026
Aug 02, 05, 12, 26, 2026
Sep 09, 23, 2026
Oct 21, Nov 18, Dec 16, 2026
Jan 13, 2027

Sun	Mon	Tue	Wed	Thu	Fri	Sat
						1 Begin overnight fast
2 Day 61 OPV Begin exercise, sauna, and steam bath restrictions	3	4 Begin overnight fast	5 Day 64 OPV	6	7	8
9 Begin exercise, sauna, and steam bath restrictions	10	11 Begin overnight fast	12 Day 71 OPV Payment 5*	13	14	15
16	17	18	19	20	21	22
23 Begin exercise, sauna, and steam bath restrictions	24	25 Begin overnight fast	26 Day 85 OPV Payment 6*	27	28	29
30	31					

Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 57)**.
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening**.
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening**.
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study**.
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study**.
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening**.
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**), and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to first Admission (Day -1)**.
- Avoid medications that impede coagulation or platelet aggregation **throughout the study**.
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening**.
- Avoid strenuous exercise for **72 hours prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.
- Avoid alcohol **within 48 hours prior to first Admission (Day -1) and throughout the study**.
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to first Admission (Day -1) and throughout the study**.
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to first Admission (Day -1) and throughout the study**.
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study**.
- Avoid the use of saunas or steam baths **within 72 hours prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.

Reminder: COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

***payment to occur within 48 hours after payment visit day**
***MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

September 2026

MEDPACE Clinical Pharmacology

SRK-439-001 MAD Cohort 8

Study Inpatient dates:

Jun 02-05, 2026
Jul 28-31, 2026

Study Outpatient dates:

Jun 07, 10, 17, 24, 2026
Jul 08, 2026
Aug 02, 05, 12, 26, 2026
Sep 09, 23, 2026
Oct 21, Nov 18, Dec 16, 2026
Jan 13, 2027

Sun	Mon	Tue	Wed	Thu	Fri	Sat
		1	2	3	4	5
6 Begin exercise, sauna, and steam bath restrictions	7 Labor Day	8 Begin overnight fast	9 Day 99 OPV	10	11	12
13	14	15	16	17	18	19
20 Begin exercise, sauna, and steam bath restrictions	21 Day 113 MRI/DEXA Window Opens*	22 Begin overnight fast	23 Day 113 OPV Payment 7* MRI/DEXA Window Closes*	24	25	26
27	28	29	30			

Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 57)**.
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening**.
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening**.
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study**.
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study**.
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening**.
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**), and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to first Admission (Day -1)**.
- Avoid medications that impede coagulation or platelet aggregation **throughout the study**.
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening**.
- Avoid strenuous exercise for **72 hours prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.
- Avoid alcohol **within 48 hours prior to first Admission (Day -1) and throughout the study**.
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to first Admission (Day -1) and throughout the study**.
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to first Admission (Day -1) and throughout the study**.
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study**.
- Avoid the use of saunas or steam baths **within 72 hours prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.

Reminder: COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

***payment to occur within 48 hours after payment visit day**
***MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

October 2026

MEDPACE

Clinical Pharmacology

SRK-439-001 MAD Cohort 8

Study Inpatient dates:

Jun 02-05, 2026
Jul 28-31, 2026

Study Outpatient dates:

Jun 07, 10, 17, 24, 2026
Jul 08, 2026
Aug 02, 05, 12, 26, 2026
Sep 09, 23, 2026
Oct 21, Nov 18, Dec 16, 2026
Jan 13, 2027

Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 57).**
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening.**
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening .**
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study.**
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study.**
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening.**
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**), and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to first Admission (Day -1).**
- Avoid medications that impede coagulation or platelet aggregation **throughout the study.**
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening.**
- Avoid strenuous exercise for **72 hours prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Avoid alcohol **within 48 hours prior to first Admission (Day -1) and throughout the study.**
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to first Admission (Day -1) and throughout the study.**
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to first Admission (Day -1) and throughout the study.**
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study.**
- Avoid the use of saunas or steam baths **within 72 hours prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**

Reminder: COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

***payment to occur within 48 hours after payment visit day**
***MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

Sun	Mon	Tue	Wed	Thu	Fri	Sat
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18 Begin exercise, sauna, and steam bath restrictions	19	20 Begin overnight fast	21 Day 141 OPV Payment 8*	22	23	23
25	26	27	28	29	30	31

November 2026

MEDPACE Clinical Pharmacology

SRK-439-001 MAD Cohort 8

Study Inpatient dates:

Jun 02-05, 2026

Jul 28-31, 2026

Study Outpatient dates:

Jun 07, 10, 17, 24, 2026

Jul 08, 2026

Aug 02, 05, 12, 26, 2026

Sep 09, 23, 2026

Oct 21, Nov 18, Dec 16, 2026

Jan 13, 2027

Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 57)**.
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening**.
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening**.
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study**.
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study**.
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening**.
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**), and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to first Admission (Day -1)**.
- Avoid medications that impede coagulation or platelet aggregation **throughout the study**.
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening**.
- Avoid strenuous exercise for **72 hours prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.
- Avoid alcohol **within 48 hours prior to first Admission (Day -1) and throughout the study**.
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to first Admission (Day -1) and throughout the study**.
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to first Admission (Day -1) and throughout the study**.
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study**.
- Avoid the use of saunas or steam baths **within 72 hours prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225)**.

Reminder: COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

***payment to occur within 48 hours after payment visit day**
***MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

Sun	Mon	Tue	Wed	Thu	Fri	Sat
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15 Begin exercise, sauna, and steam bath restrictions	16	17 Begin overnight fast	18 Day 169 OPV Payment 9*	19	20	21
22	23	24	25	26 Thanksgiving	27	28
29	30					

December 2026

MEDPACE
Clinical Pharmacology

SRK-439-001 MAD Cohort 8

Study Inpatient dates:

Jun 02-05, 2026
Jul 28-31, 2026

Study Outpatient dates:

Jun 07, 10, 17, 24, 2026
Jul 08, 2026
Aug 02, 05, 12, 26, 2026
Sep 09, 23, 2026
Oct 21, Nov 18, Dec 16, 2026
Jan 13, 2027

Sun	Mon	Tue	Wed	Thu	Fri	Sat
		1	2	3	4	5
6	7	8	9	10	11	12
13 Begin exercise, sauna, and steam bath restrictions	14	15 Begin overnight fast	16 Day 197 OPV Payment 10*	17	18	19
20	21	22	23	24	25 Christmas	26
27	28	29	30	31		

Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 57).**
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening.**
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening .**
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study.**
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study.**
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening.**
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**), and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to first Admission (Day -1).**
- Avoid medications that impede coagulation or platelet aggregation **throughout the study.**
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening.**
- Avoid strenuous exercise for **72 hours prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Avoid alcohol **within 48 hours prior to first Admission (Day -1) and throughout the study.**
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to first Admission (Day -1) and throughout the study.**
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to first Admission (Day -1) and throughout the study.**
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study.**
- Avoid the use of saunas or steam baths **within 72 hours prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**

Reminder: COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

***payment to occur within 48 hours after payment visit day**
***MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

January 2027

MEDPACE

Clinical Pharmacology

SRK-439-001 MAD Cohort 8

Study Inpatient dates:

Jun 02-05, 2026
Jul 28-31, 2026

Study Outpatient dates:

Jun 07, 10, 17, 24, 2026
Jul 08, 2026
Aug 02, 05, 12, 26, 2026
Sep 09, 23, 2026
Oct 21, Nov 18, Dec 16, 2026
Jan 13, 2027

Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 57).**
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening.**
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening .**
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study.**
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study.**
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening.**
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**), and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to first Admission (Day -1).**
- Avoid medications that impede coagulation or platelet aggregation **throughout the study.**
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening.**
- Avoid strenuous exercise for **72 hours prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Avoid alcohol **within 48 hours prior to first Admission (Day -1) and throughout the study.**
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to first Admission (Day -1) and throughout the study.**
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to first Admission (Day -1) and throughout the study.**
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study.**
- Avoid the use of saunas or steam baths **within 72 hours prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to each admission (Days -1 and 56) and each clinic visit (Days 5, 8, 15, 22, 36, 61, 64, 71, 85, 99, 113, 141, 169, 197, and 225).**

Reminder: COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

***payment to occur within 48 hours after payment visit day**
***MRI/DEXA: A staff member from Cincinnati Children's will contact you with further details.**

Sun	Mon	Tue	Wed	Thu	Fri	Sat
					1 New Year's Day	2
3	4	5	6 Day 225 MRI/DEXA Window Opens*	7	8	9
10 Begin exercise, sauna, and steam bath restrictions	11	12 Begin overnight fast	13 Day 225 OPV (EOS) Payment 11* MRI/DEXA Window Closes*	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31						